Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
The MISSION! Intervention Study: A Prospective Randomised Controlled Trial to Evaluate the Efficacy of Drug-Eluting Stents versus Bare-Metal Stents for the Treatment of Acute Myocardial Infarction
ISRCTN ISRCTN62825862
ClinicalTrials.gov identifier
Public title The MISSION! Intervention Study: A Prospective Randomised Controlled Trial to Evaluate the Efficacy of Drug-Eluting Stents versus Bare-Metal Stents for the Treatment of Acute Myocardial Infarction
Scientific title
Acronym MISSION! Intervention Study
Serial number at source NTR396
Study hypothesis Thin strut cobalt chromium stents are not inferior in preventing restenosis compared to sirolimus-eluting stents in patients with acute myocardial infarction.
Ethics approval Received from local medical ethics committee
Study design Randomised open label controlled parallel group trial
Countries of recruitment Netherlands
Disease/condition/study domain Acute myocardial infarction
Participants - inclusion criteria 1. Between 18 and 80 years of age
2. ECG evidence of an acute myocardial infarction
3. De novo native culprit lesion
4. Target vessel with a reference diameter between 2.25 and 3.75 mm
5. Target lesion length ≤ 24 mm
6. Written informed consent
Participants - exclusion criteria 1. Rescue PTCA
2. Start symptoms >9 hours before the procedure
3. Left main lesion with ≥ 50% diameter stenosis
4. Triple vessel disease
5. Involvement of a major side branch
6. Previous PCI or CABG of the culprit vessel
7. Renal insufficiency
8. Unwilling or unable to comply with the study requirements or follow-up evaluations
9. Contraindication for abciximab
10. Extensive peripheral vascular disease
11. Non-cardiac illness with a life expectancy less than 12 months
Anticipated start date 01/02/2004
Anticipated end date 31/01/2006
Status of trial Completed
Patient information material
Target number of participants 300
Interventions The MISSION! Intervention Study is a prospective randomised study comparing non-coated, thin strut, cobalt chromium stents (Vision™) and sirolimus eluting stents (Cypher™) for the treatment of patients with acute myocardial infarction.
300 patients will be randomised and treated by primary percutaneous coronary intervention with stent implantation. All patients will have angiographic follow-up at 9 months to assess the primary endpoint with Quantitative Coronary Angiography. In all patients, IVUS will be performed post-intervention and at 9 months follow-up to assess acute and late incomplete stent apposition and neointimal volume.
Moreover fractional flow reserve will be measured at 9 months to assess functional stent patency. At 12 months major adverse events will be counted and analysed according to life table methods.
Clinical and angiographic data will be analyzed according to the principle of intention-to-treat and evaluable group analyses. End-point variables will be presented by means of 95% confidence intervals.
Primary outcome measure(s) In-lesion late loss at 9 months
Secondary outcome measure(s) 1. MACE (death, myocardial infarction, target vessel revascularisation, target lesion revascularisation) at 12 months
2. Incomplete stent apposition at 9 months
3. Minimal lumen area at 9 months
4. Fractional flow reserve at 9 months
Sources of funding 1. Dutch Heart Foundation (Nederlandse Hartstichting [NHS]) (Netherlands)
2. Guidant Inc. (USA)
Trial website
Publications 1. 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/19463300
2. 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/20142177
Contact name Prof  M.J.  Schalij
  Address Leiden University Medical Center
Department of Cardiology
P.O. Box 9600
  City/town Leiden
  Zip/Postcode 2300 RC
  Country Netherlands
  Tel +31 (0)71 5264811
  Fax +31 (0)71 5266809
  Email m.j.schalij@lumc.nl
Sponsor Leiden University Medical Centre, Department of Cardiology (Netherlands)
  Address P.O. Box 9600
  City/town Leiden
  Zip/Postcode 2300 RC
  Country Netherlands
Date applied 27/01/2006
Last edited 13/08/2010
Date ISRCTN assigned 27/01/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central